<DOC>
	<DOCNO>NCT02443324</DOCNO>
	<brief_summary>The main purpose study evaluate safety preliminary efficacy combination study drug know ramucirumab plus pembrolizumab participant locally advance unresectable metastatic gastric gastroesophageal junction ( GEJ ) adenocarcinoma , non-small cell lung cancer ( NSCLC ) , transitional cell carcinoma urothelium , biliary tract cancer ( BTC ) .</brief_summary>
	<brief_title>A Study Ramucirumab Plus Pembrolizumab Participants With Gastric GEJ Adenocarcinoma , NSCLC , Transitional Cell Carcinoma Urothelium , Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Metastatic disease locally advance , unresectable disease . Has histopathologically confirm gastric GEJ adenocarcinoma document disease progression 02 prior line systemic therapy Has histopathologically confirm nonsquamous squamous NSCLC document disease progression 03 prior line systemic therapy Has histopathologically confirm transitional cell carcinoma urothelium ( bladder , urethra , renal pelvis ) document disease progression 13 prior line systemic therapy Has histologically confirm biliary tract adenocarcinoma document progression 12 prior line systemic therapy Availability tumor tissue biomarker analysis newly obtain core excisional biopsy willing undergo tumor biopsy . For first line NSCLC participant , PDL1 expression 1 % high . Have Eastern Cooperative Oncology Group Performance Status 0 1 . Has adequate organ function . Have anticipate life expectancy ≥3 month . Have know brain metastasis . Has receive ≥3 line prior systemic therapy gastric GEJ adenocarcinoma BTC ≥4 line NSCLC urothelial cancer . Has active autoimmune disease . Known human immunodeficiency virus ( HIV ) infection . Known active hepatitis B hepatitis C infection . Has receive previous systemic therapy target vascular endothelial growth factor ( VEGF ) VEGF receptor , program death ( PD ) 1 PDligand 1/2 signal pathway . Have receive live vaccine within 30 day prior enrollment . Seasonal flu vaccine contain live virus permit . Have serious nonhealing wound , ulcer , bone fracture within 28 day prior enrollment . Have elective plan major surgery course trial undergone major surgery within 28 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>immuno-oncology</keyword>
	<keyword>Vascular Endothelial Growth Factor ( VEGF )</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>PD-1</keyword>
	<keyword>carcinoma bladder</keyword>
	<keyword>carcinoma urethra</keyword>
	<keyword>carcinoma ureter</keyword>
	<keyword>carcinoma renal pelvis</keyword>
	<keyword>carcinoma biliary tract</keyword>
</DOC>